|
|
|
15.04.26 - 23:01
|
Portal CEO on Lilly Deal for Cancer Biotech CrossBridge (Bloomberg)
|
|
|
Portal Innovations CEO John Flavin provides a look into the 2026 biotech M&A pipeline and breaks down Eli Lilly's purported acquisition of CrossBridge Bio for up to $300 million, bolstering its oncology segment. He talks with Katie Greifeld and Romaine Bostick on “The Close.” (Source: Bloomberg)...
|
|
|
|
|
|
|
14.04.26 - 15:06
|
Linden Lake Labs Applauds Acquisition of Portfolio Company CrossBridge Bio by Eli Lilly and Company (Business Wire)
|
|
|
Transaction validates dual-payload ADC platform and reinforces Linden Lake Labs' life sciences platform for advancing breakthrough therapiesROCKVILLE, Md.--(BUSINESS WIRE)--Linden Lake Labs (“L3”), an early-stage life sciences platform committed to advancing innovative therapies, today announced that its portfolio company, CrossBridge Bio, has entered into a definitive agreement to be acquired by Eli Lilly and Company.
Linden Lake Labs participated in CrossBridge Bio's seed financing round in November 2024, supporting the early development of its differentiated dual-payload antibody-drug conjugate (ADC) platform.
“This milestone reflects the power of investing early in pioneering science and exceptional teams,” said Abhishake Chhibber, Co-Founder of Linden Lake Labs. “At Linden Lake Labs, we are committed to advancing innovative therapies through a life sciences platform—bringing together scientific founders, capital, and strategic capabilities to accelerate breakthrough medicines. CrossBrid...
|
|
|
|
|
14.04.26 - 14:39
|
Eli Lilly lässt nicht locker: Nächste Übernahme (Der Aktionaer)
|
|
|
Der US-amerikanische Pharma-Riese schwimmt dank einer anhaltenden, dynamischen Nachfrage nach seinen Diabetes- und Abnehmmitteln auf der Erfolgswelle. Doch Eli Lilly ruht sich darauf nicht aus, im Gegenteil. Das Unternehmen hat zuletzt mehrere Übernahmen eingefädelt – am Dienstag kommt eine weitere M&A-Transaktion hinzu....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.04.26 - 18:12
|
Eli Lilly vs. Novo Nordisk: The Obesity Drug Race Has a New Leader (24/7 Wall St.)
|
|
|
Eli Lilly and Company (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) reported quarterly results in early February, and the gap between them has widened significantly. Lilly's tirzepatide franchise is accelerating. Novo is cutting jobs, warning of a sales decline, and leaning on a newly launched pill to stabilize its position. Tirzepatide Pulls Away. Semaglutide Faces the ... Eli Lilly vs. Novo Nordisk: The Obesity Drug Race Has a New Leader...
|
|
|
10.04.26 - 14:31
|
Who Benefits From Amazon Pharmacy Stocking Eli Lilly’s New Weight Loss Pill (24/7 Wall St.)
|
|
|
Amazon (NASDAQ: AMZN) just made a quiet move that could reshape how Americans access weight-loss drugs. On April 9, 2026, it announced that its pharmacy unit will stock new GLP-1 weight-loss pill Foundayo at One Medical kiosks and offer same-day home delivery, with plans to expand that access to 4,500 locales by end of 2026. ... Who Benefits From Amazon Pharmacy Stocking Eli Lilly's New Weight Loss Pill...
|
|
|
|
|
|
|
10.04.26 - 08:15
|
Novo Nordisk: Auch das noch – Top-Forscherin geht (Der Aktionaer)
|
|
|
Novo Nordisk hat die Pole-Position im wachstumsstarken Adipositas-Markt aus der Hand gegeben. Der große US-Wettbewerber Eli Lilly ist inzwischen enteilt. Und nun muss Novo Nordisk auch noch den Abgang der Top-Forscherin Lotte Bjerre Knudsen hinnehmen, die maßgeblich die Entwicklung von Appetitzüglern bei den Dänen geprägt hat....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
